Is the business good?
How good a business is SHC?
Sotera Health Company keeps 13% of every revenue dollar as profit after everything, against 6.7% for the median Diagnostics & Research name.
13%
Net margin · Diagnostics & Research median 6.7% · 12 months to Q2 2026
- Cash conversion
- 0.69×
Cash conversion · some of the reported profit has not turned into cash yet
- Share count, year on year
- +0.84%
Share count, year on year · flat: no meaningful dilution
- Gross margin
- 55%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 25% |
| FY2021 | 28% |
| FY2022 | 25% |
| FY2023 | 26% |
| FY2024 | 27% |
Details›
- Gross margin12 months to Q2 2026
- 55%
- Net margin12 months to Q2 2026
- 13%
- Free cash flow margin
- 9.3%
- Revenue, trailing twelve months
- $1.22B
- Free cash flow, trailing twelve months
- $113M
- Net income, trailing twelve months
- $163M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Diagnostics & Research
Ranks #18 of 29 by Smart Score